NASDAQ:INKT

Mink Therapeutics Stock Insider Trading

etoro logo Buy INKT
*Your capital is at risk
$12.33
+0.0800 (+0.653%)
At Close: Jun 23, 2026

MiNK Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 69.57. In total, the insiders bought 761.33K and sold 24.23K INKT shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
69.57
Buy 761.33K shares
Sell 24.23K shares
89% Buy Activity
Negligible or No Correlation
Sell Signal Low Confidence
Jun 04, 2026

Analysis Breakdown:

  • Signal is highly questionable due to a strongly contradictory positive Insider Power Score of 69.57.
  • Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date Type Person Role Amount
Jun 04, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 1 000
Value: $12.8K
Jun 04, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 500
Value: $6K
Jun 01, 2026
Buy
Common Stock
A-Award
Wiinberg Ulf
Director
Director 1 131
Value: $14.0K
Jun 01, 2026
Buy
Common Stock
A-Award
Behner Peter
Director
Director 1 313
Value: $16.3K
Jun 01, 2026
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 1 444
Value: $17.9K
Jun 01, 2026
Buy
Common Stock
A-Award
Ryan Barbara
Director
Director 1 434
Value: $17.8K
Jun 01, 2026
Buy
Common Stock
A-Award
Holcomb John Bradley
Director
Director 1 091
Value: $13.5K
Mar 13, 2026
Buy
Common Stock
Orilall Melissa
Principal Financial Officer
Officer 0
Value: $0
Mar 13, 2026
Buy
Common Stock
Charette Austin
Principal Accounting Officer
Officer 0
Value: $0
Mar 10, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 500
Value: $8K
Mar 10, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 500
Value: $8K
Mar 10, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 300
Value: $5K
Mar 09, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 200
Value: $2K
Mar 02, 2026
Buy
Common Stock
A-Award
Wiinberg Ulf
Director
Director 1 285
Value: $14.0K
Mar 02, 2026
Buy
Common Stock
A-Award
Behner Peter
Director
Director 1 491
Value: $16.3K
Mar 02, 2026
Buy
Common Stock
A-Award
Corvese Brian
Director
Director 1 640
Value: $17.9K
Mar 02, 2026
Buy
Common Stock
A-Award
Ryan Barbara
Director
Director 1 629
Value: $17.8K
Mar 02, 2026
Buy
Common Stock
A-Award
Holcomb John Bradley
Director
Director 1 239
Value: $13.5K
Mar 02, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 100
Value: $1K
Feb 27, 2026
Sell
Common Stock
S-Sale
Ryan Barbara
Director
Director 400
Value: $4K
Jan 02, 2026
Sell
Common Stock
F-InKind
Buell Jennifer
Chief Executive Officer
CEO / President 10 024
Value: $111.5K
Jan 02, 2026
Buy
Stock Option (Right to Buy)
A-Award
Behner Peter
Director
Director 5 395
Value: $60.0K
Jan 02, 2026
Buy
Stock Option (Right to Buy)
A-Award
Corvese Brian
Director
Director 5 395
Value: $60.0K
Jan 02, 2026
Buy
Stock Option (Right to Buy)
A-Award
Ryan Barbara
Director
Director 5 395
Value: $60.0K
Jan 02, 2026
Buy
Stock Option (Right to Buy)
A-Award
Wiinberg Ulf
Director
Director 5 395
Value: $60.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT MINK THERAPEUTICS, INC.
MiNK Therapeutics
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials. The company was former...
GOLDEN STAR
Ticker Change Signal Date
IDYA
$28.98
18.12% Jun 12
DHI
$146.71
6.29% Jun 10
PHM
$118.49
6.02% Jun 10
EAT
$140.46
17.09% Jun 05
E
ETD
$20.67
3.19% Jun 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE